InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo has 4 licensing announcements in this dataset, dated 2026-01-05 to 2026-07-02.
- Country / operating region
- China
- Ticker
- 03696.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- AI-enabled drug discovery and development
- Website
- insilico.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Oncology discovery programs | 查無 | 查無 | preclinical | 2026-01-05 |
| Novel oral therapeutic candidates and discovery programs | 查無 | small molecule | preclinical | 2026-03-29 |
| AI-designed neuroimmune candidates | 查無 | small molecule | preclinical | 2026-06-22 |
| Drug discovery collaboration candidates | 查無 | 查無 | preclinical | 2026-07-02 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | Servier | Oncology discovery programs | 查無 | 查無 | 查無 | ≤ USD 888m | Combined upfront + near-term ≤ USD 32m |
| 2026-03-29 | Eli Lilly and Company | Novel oral therapeutic candidates and discovery programs | USD 115m | 查無 | 查無 | ≈ USD 2750m | — |
| 2026-06-22 | SK Biopharmaceuticals | AI-designed neuroimmune candidates | 查無 | 查無 | 查無 | 查無 | Combined upfront + near-term ≤ USD 18m Potential total > USD 2500m |
| 2026-07-02 | Takeda Pharmaceutical Company Limited | Drug discovery collaboration candidates | 查無 | 查無 | 查無 | ≈ USD 600m | Combined initiation + near-term + milestones ≈ USD 60m |
| Counterparty | Territory | Royalties |
|---|---|---|
| Servier | 查無 | 查無 |
| Eli Lilly and Company | Worldwide | Tiered royalties on future sales. |
| SK Biopharmaceuticals | Worldwide | Single-digit royalties on net sales. |
| Takeda Pharmaceutical Company Limited | Worldwide | Tiered royalties on future sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無